New drug - Volibris
GSK has launched Volibris (ambrisentan) for the treatment of pulmonary arterial hypertension (WHO Cl... Read more
Motivation is central to human behaviour. Yet although doctors and nurses begin as some of the most ... Read more
Why won't this government admit its mistakes? MPIG is a classic example. Read more
The National Programme for IT (NPfIT) is now four years behind schedule and will cost £300 million m... Read more
In all the doom and gloom of our chaotic NHS, it really is good once in a while to be able to report... Read more
Parkinson's third law says 'Growth leads to complexity, complexity to decay'. It couldn't describe t... Read more
The NHS is approaching its 60th birthday and Lord Darzi is about to publish his review, so I thought... Read more
One of the least-recognised attributes of a truly free market is that it contains a lot of informati... Read more
The economist Milton Friedman made a telling observation: the care with which we spend money depends... Read more
One of the less attractive aspects of the purchaser-provider split is the ham-fisted way in which pr... Read more
I was delighted to hear that NHS managers have been taken aback by the strength of feeling against t... Read more
GSK has launched Volibris (ambrisentan) for the treatment of pulmonary arterial hypertension (WHO Cl... Read more
Thymoglobuline is an immunosuppressant for the prophylaxis of graft rejection in renal or heart tra... Read more
Tyverb (lapatinib) is an oral antineoplastic agent that may provide women with an alternative option... Read more